Department of Physiology, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology.
Department of Cardiology.
J Card Fail. 2019 Jun;25(6):468-478. doi: 10.1016/j.cardfail.2019.03.008. Epub 2019 Mar 14.
Congestive heart failure (CHF) entails a complex interaction between the heart and the kidney that represents a clinical entity called cardiorenal syndrome (CRS). One of the mechanisms underlying CRS includes increased intra-abdominal pressure (IAP). We examined the effect of elevated IAP on kidney function in rats with low- and high-output CHF.
Rats with compensated and decompensated CHF induced by means of aortocaval fistula, rats with myocardial infraction (MI) induced by means of left anterior descending artery ligation, and sham control rats were subjected to either 10 or 14 mm Hg IAP. Urine flow (V), Na excretion (UV), glomerular filtration rate (GFR), and renal plasma flow (RPF) were determined. The effects of pretreatment with tadalafil (10 mg/kg orally for 4 days) on the adverse renal effects of IAP were examined in decompensated CHF and MI. Basal V and GFR were significantly lower in rats with decompensated CHF compared with sham control rats. Decompensated CHF rats and MI rats subjected to 10 and 14 mm Hg IAP exhibited more significant declines in V, UV, GFR and RPF than compensated and sham controls. Elevated IAP also induced tubular injury, as evidenced by significantly increased absolute urinary excretion of neutrophil gelatinase-associated lipocalin. In addition, in a nonquantitative histologic analysis, elevated IAP was associated with increase in necrosis and cell shedding to the tubule lumens, especially in the decompensated CHF subgroup. Pretreatment of decompensated CHF rats and MI rats with tadalafil ameliorated the adverse renal effects of high IAP.
Elevated IAP contributes to kidney dysfunction in high- and low-cardiac output CHF. IAP induces both hemodynamic alterations and renal tubular dysfunction. These deleterious effects are potentially reversible and can be ameliorated with the use of phosphodiesterase-5 inhibition.
充血性心力衰竭(CHF)涉及心脏和肾脏之间的复杂相互作用,代表一种称为心肾综合征(CRS)的临床实体。CRS 的机制之一包括腹内压(IAP)升高。我们检查了升高的 IAP 对低输出和高输出 CHF 大鼠肾功能的影响。
通过腹主动脉-腔静脉瘘诱导的代偿性和失代偿性 CHF 大鼠、通过左前降支结扎诱导的心肌梗死(MI)大鼠和假手术对照大鼠分别接受 10 或 14mmHg 的 IAP。测定尿量(V)、Na 排泄(UV)、肾小球滤过率(GFR)和肾血浆流量(RPF)。在失代偿性 CHF 和 MI 中,检查了预先给予他达拉非(10mg/kg 口服 4 天)对 IAP 不良肾脏作用的影响。与假手术对照大鼠相比,失代偿性 CHF 大鼠的基础 V 和 GFR 明显降低。10 和 14mmHg IAP 下的失代偿性 CHF 大鼠和 MI 大鼠的 V、UV、GFR 和 RPF 下降更为显著,与代偿性和假手术对照组相比。升高的 IAP 还会引起肾小管损伤,这表现为中性粒细胞明胶酶相关脂质运载蛋白的绝对尿排泄明显增加。此外,在非定量组织学分析中,升高的 IAP 与肾小管腔中坏死和细胞脱落的增加有关,尤其是在失代偿性 CHF 亚组中。预先给予失代偿性 CHF 大鼠和 MI 大鼠他达拉非可改善高 IAP 的不良肾脏作用。
升高的 IAP 导致高输出和低输出 CHF 时肾功能障碍。IAP 引起血流动力学改变和肾小管功能障碍。这些有害影响是潜在可逆的,可以通过使用磷酸二酯酶-5 抑制来改善。